BMS Product definition
Examples of BMS Product in a sentence
Within three (3) months of the Effective Date, BMS and Licensee shall enter into a separate written agreement consistent with this Article 17 and containing mutually acceptable guidelines and procedures for the receipt, recordation, communication (as between BMS and Licensee) and exchange of adverse event information for the Product and the BMS Product (the "Safety Data Exchange Agreement").
BMS and Licensee shall exchange serious adverse events associated with the Product and the BMS Product, including those from clinical trial cases and those reported to be related to biomedical research.
BMS shall record, investigate, obtain additional information, summarize and review all adverse events reported to it which are associated with the BMS Product.
In addition, all reports of exposure to the Product or the BMS Product during pregnancy and all reports of overdoses of the Product or the BMS Product will be exchanged regardless of whether they result in an adverse event/reaction.
BMS shall maintain, at its own expense, a safety database which shall reference any adverse event/reaction associated with the BMS Product occurring anywhere in the world.
For each BMS Product, BMS shall make to Exelixis the following milestone payments set forth below within [ * ] of the achievement of each of the following events: (a) [ * ] upon filing the first NDA in a Major Market for any New Indication for a BMS Product; and (b) [ * ] upon approval of such NDA in a Major Market.
In the event that BMS wishes to enter into such an arrangement for such Specified BMS Product on more favorable terms to the Third Party than the BMS Minimum Terms, then BMS shall first reoffer such Specified BMS Product to Sano on substantially the same terms as those offered to such Third Party.
Such license for a particular Pharmacogenomic Product shall be sublicensable solely (x) together with a sublicense under Section 5.1(a)(ii) with respect to a related BMS Product or (y) by BMS or its sublicensee, for the purpose of developing or commercializing a Pharmacogenomic Product for use in conjunction with a related BMS Product that BMS or its sublicensee is developing or commercializing.
Sano shall have 30 business days after receipt of such notice and information to decide whether or not it wishes to pursue negotiations for such an arrangement with respect to such Specified BMS Product.
Each milestone payment set forth in this Section 7.3(f) will be paid only once with respect to a given BMS Product, regardless of the number of indications sought or approved for such BMS Product.